SAN DIEGO, June 22 /PRNewswire/ -- SEQUENOM, Inc. (Nasdaq: SQNM) announced
today that it will be among the leading healthcare and biotechnology companies
presenting at the BIO 2001 International Convention and Exhibition,
June 24th-27 in San Diego, with over 12,000 international participants
expected to attend. SEQUENOM featured panels and participants will include:
Strategies in Pharmacogenomics
Toni Schuh, President & CEO
Monday, June 25, 10:15 a.m., Upper Level, Room 7
Post Genomics: Making Sense of DNA's Secrets
Andreas Braun, M.D., Ph.D., Chief Medical Officer
Monday, June 25, 4:00 p.m., Upper Level, Room 9
Impact of Nucleic Acid Probe Technology on the Future of Clinical
Microbiology: Accurate and High-Throughput Genotyping with MassARRAY(TM)
Matthew J. McGinniss, Ph.D., Group Leader
Tuesday, June 26, 4:00 p.m., Mezzanine Level, Room 16B
SEQUENOM Investor Presentation
Steve Zaniboni, Chief Financial Officer
Wednesday, June 27, 10:00 a.m., Sails Pavilion, Room C
View this event live or archived at http://www.informedinvestors.com
About SEQUENOM
SEQUENOM is a leader in the worldwide effort to identify genes and genetic
variations with significant impact on human health. Using its innovative
technologies, information and scientific strategy, the Company is translating
data generated from the Human Genome Project into medically important
applications. Breaking through the limitations of traditional genomic
research, SEQUENOM's MassARRAY product line, SNP assay portfolio and disease
gene discovery program are generating results that position SEQUENOM and its
partners to lead the race in developing genetics-based diagnostic and
therapeutic products.
All statements in this press release that are not historical are forward-
looking statements within the meaning of the Securities Exchange Act of 1934
as amended. Such forward-looking statements are subject to factors that could
cause actual results to differ materially for SEQUENOM from those projected.
Those factors include risks and uncertainties relating to technological
approaches of SEQUENOM and its collaborators and competitors, product
development, manufacturing, market acceptance, cost and pricing of SEQUENOM
products, dependence on collaborative partners and commercial customers,
successful performance under collaborative and commercial agreements,
competition, the intellectual property of others, patent protection and other
risk factors discussed from time to time in SEQUENOM's reports and filings
with the Securities and Exchange Commission, including SEQUENOM's Annual
Report on Form 10-K for the year ended December 31, 2000. SEQUENOM expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any
change in SEQUENOM's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
SOURCE SEQUENOM, Inc.
 back to top
Related links:
http://www.sequenom.com
Company News On-Call:
http://www.prnewswire.com/comp/124192.html or fax,
800-758-5804, ext. 124192
CONTACT:
Abigail Devine, APR, Investor Relations of
SEQUENOM, Inc., 858-202-9032, adevine@sequenom.com
|
